Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

AIMS: The metabolic pathways leading to the formation of prasugrel and clopidogrel active metabolites differ. We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. METHODS AND RESULTS: Ninety-eight patients with cor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Varenhorst, Christoph, James, Stefan, Erlinge, David, Brandt, John T., Braun, Oscar Ö., Man, Michael, Siegbahn, Agneta, Walker, Joseph, Wallentin, Lars, Winters, Kenneth J., Close, Sandra L.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2009
Assuntos:
Clinical Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2709885/
https://ncbi.nlm.nih.gov/pubmed/19429918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehp157
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados